Editorial: Probiotics and their metabolites in cancer therapy
Pourya Gholizadeh,Amir Hossein Faghfouri,Pio Maria Furneri,Elnaz Faghfuri
DOI: https://doi.org/10.3389/fphar.2024.1497524
IF: 5.6
2024-10-10
Frontiers in Pharmacology
Abstract:The bacterial strains of probiotics can be either naïve or genetically modified in any way. When utilized in dietary supplements, they are referred to as "live microbiological ingredients," when used as a drug, they are known as "live biotherapeutic agents." Most probiotics are categorized into bifidobacterial and lactic acid bacterial strains. However, certain bacteria and yeasts are also classified as probiotics. Probiotics play critical roles in preventing and effectively treating various types of cancer (Faghfuri et al., 2024;Feizi et al., 2024). Probiotics and their pro-bioactive cellular materials offer numerous therapeutic benefits for the gastrointestinal tract, including the release of various enzymes and potential synergistic effects on digestion. Specific components of probiotic lactic acid bacteria can modulate immune responses, activate the reticuloendothelial system, enhance cytokine pathways, and regulate interleukins and tumor necrosis factors. The primary mechanisms through which probiotics exert anticancer and antimutagenic effects include the binding, degradation, and inhibition of mutagens; preventing the production of procarcinogens and the transformation of harmful carcinogens; lowering the gut pH by producing short-chain fatty acids (SCFAs) from nondigestible carbohydrates; and enhancing the host's innate immunity through the secretion of anti-inflammatory molecules. As essential dietary supplements, probiotics play a valuable role in reducing cancer risk and ensuring the safety of chemotherapy, radiation therapy, and surgery, with minimal side effects (Faghfuri et al., 2024;Feizi et al., 2024). Therefore, investigating potential probiotic strains, effective dosages, and molecular mechanisms that can support cancer therapy is crucial. This research topic highlights the potential roles of live and dead probiotics, along with their metabolic products, in cancer treatment and the exploration of alternative therapeutic mechanisms.The research topic delves into five articles that thoroughly investigate the use of probiotics and their metabolites for treating various types of cancer. Recent studies have explored the potential of probiotics as oral vaccines, which carry fewer risks than pathogenic alternatives do. These oral vaccines can stimulate mucosal immunity, helping to protect against intestinal infections. Probiotic bacteria can produce metabolites such as anti-inflammatory cytokines, which are crucial for preventing cancer development and activating phagocytes to eradicate early-stage cancer cells. In addition to probiotics, their secreted products, including bacteriocins, exopolysaccharides, SCFAs, conjugated linoleic acid, peptidoglycan, and other metabolites, have shown anticancer properties.The beneficial effects of these postbiotic compounds have been extensively studied to understand their mechanisms of action in reducing cancer growth. Sudaarsan et al. focused primarily on the postbiotic components used against cancer and their documented mechanisms of action. This research also outlines recent studies conducted to examine specific strains and the anticancer activity of derived compounds, both in laboratory settings and in living organisms, confirming that the probiotic approach could offer an alternative strategy for alleviating the burden of cancer. Additionally, the application of microbiota therapy in the treatment and prognosis of gastric cancer has been discussed. The presence of the microbiota has a twofold effect on gastric cancer. First, it can contribute to the progression of gastric cancer and negatively influence its treatment and prognosis through pathogenic bacterial infections and dysbiosis. Second, there is a potential for microbial therapies to address gastric cancer by optimizing the microbiota through dietary modifications, employing bacteriophages and probiotics, and even resorting to FMT. However, after considering the in vivo and in vitro studies mentioned, further research through clinical trials is essential to fully establish the anticancer properties of probiotics. Extensive human trials are also necessary to verify the effectiveness of this approach. Indeed, it is crucial to carefully plan experiments to assess the positive and negative effects of probiotics. Further studies should focus on conducting more in-depth research to elucidate the molecular mechanisms of newly discovered probiotic strains derived from functional dairy and nondairy food products, thereby bridging the gap between the food and pharmaceutical sectors.
pharmacology & pharmacy